Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Century Therapeutics reported strong Q2 2026 results highlighting significant progress in its iPSC-derived cell therapy pipeline, including a positive pre-IND meeting with the FDA for CNTY-813 targeting type 1 diabetes functional cure and ongoing preparations for CNTY-308 clinical trials in B-cell diseases. The company established Phase 1 manufactu…